Skip to main content
. 2021 May;10(5):2148–2162. doi: 10.21037/tlcr-21-214

Figure 2.

Figure 2

Treatment outcomes of ICIs in patients with and without COPD. (A) Kaplan-Meier curve of OS by COPD (including spirometry-defined COPD and physician-diagnosed COPD). (B) Kaplan-Meier analysis of the PFS probability by COPD. The dotted lines indicate median survival time. Patients with COPD appear to gain longer survival time, and were significantly associated with better PFS in our cohort (316 vs. 186 days; adjusted HR, 0.56; 95% CI, 0.33–0.96; P=0.018). COPD, chronic obstructive pulmonary disease; ICI, immune checkpoint inhibitor; OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval.